scLR
scLR identifies and analyzes dysregulated ligand-receptor interactions between conditions using single-cell transcriptomic data to characterize changes in cell-cell communication.
Key Features:
- Simultaneous consideration of ligands and receptors: Considers ligand and receptor expression jointly to identify dysregulated interactions across multiple conditions.
- Statistical modeling of expression product: Models the distribution of the product of ligand and receptor expression values to assess interaction changes.
- Accounting for inter-sample variance and small sample sizes: The modeling approach explicitly accounts for inter-sample variances and limited sample sizes common in single-cell studies.
- Validation by simulation studies: Simulation studies demonstrate high sensitivity and specificity for detecting significant changes in interactions.
Scientific Applications:
- Study of cellular communication in biological processes: Applicable to investigations of differentiation, development, homeostasis, and inflammation.
- Cytokine signaling in COVID-19: Used to uncover cytokine signaling between macrophages and proliferating T cells during severe acute COVID-19 infection.
- TGF-β signaling in pulmonary fibrosis: Identified activated TGF-β signaling from alveolar type II cells in the pathogenesis of pulmonary fibrosis.
Methodology:
Models the distribution of the product of ligand and receptor expressions and incorporates inter-sample variance and small sample size considerations to detect dysregulated interactions across conditions.
Topics
Details
- License:
- Not licensed
- Cost:
- Free of charge
- Tool Type:
- library
- Operating Systems:
- Mac, Linux, Windows
- Programming Languages:
- R
- Added:
- 7/25/2022
- Last Updated:
- 11/24/2024
Operations
Publications
Liu Q, Hsu C, Li J, Shyr Y. Dysregulated ligand–receptor interactions from single-cell transcriptomics. Bioinformatics. 2022;38(12):3216-3221. doi:10.1093/bioinformatics/btac294. PMID:35482476. PMCID:PMC9191214.
PMID: 35482476
PMCID: PMC9191214
Funding: - National Cancer Institute: U2C CA233291, U54 CA217450
- National Institutes of Health: P01 AI139449
- Cancer Center Support Grant: P30CA068485